{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:30:59Z","timestamp":1789605059586,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["FTLDc 01GI1007A"],"award-info":[{"award-number":["FTLDc 01GI1007A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU Joint Programme-Neurogenerative Diseases networks Genfi-Prox","award":["01ED2008A"],"award-info":[{"award-number":["01ED2008A"]}]},{"name":"EU","award":["MOODMARKER 01EW2008"],"award-info":[{"award-number":["MOODMARKER 01EW2008"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1279"],"award-info":[{"award-number":["SFB1279"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008316","name":"Baden-W\u00fcrttemberg Stiftung","doi-asserted-by":"publisher","award":["D.3830"],"award-info":[{"award-number":["D.3830"]}],"id":[{"id":"10.13039\/100008316","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehring Ingelheim Ulm University BioCenter","award":["D.5009"],"award-info":[{"award-number":["D.5009"]}]},{"DOI":"10.13039\/100009281","name":"Fondation Thierry Latran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009281","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Faculty of Martin-Luther-University Halle-Wittenberg","award":["JCS24\/02"],"award-info":[{"award-number":["JCS24\/02"]}]},{"DOI":"10.13039\/100030902","name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030902","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Neuromuscular diseases (NMDs) and mitochondriopathies are rare and heterogeneous disorders. Diagnosis is often difficult and delayed, partly due to the lack of reliable biomarkers. Chitotriosidase (CHIT1) as a candidate marker for lysosomal storage diseases is elevated in Niemann pick disease type C as a prototype of this group of diseases. Most recently, a relevant role of the lysosomal pathway in mitochondriopathies has been discussed, but markers of lysosomal involvement have not been investigated. Therefore, the aim of this study was to evaluate CHIT1 concentrations in a broad spectrum of NMDs and mitochondriopathies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>CHIT1 serum concentration of 151 patients with NMD or primary mitochondriopathy was determined by enzyme-linked immunosorbent assay, and compared to 38 healthy controls and 8 patients with Niemann pick disease type C. Results were controlled for age, sex, CRP and CHIT1 polymorphism, and compared to several established markers (CK, FGF21, GDF15).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>CHIT1 levels were not altered in NMDs, but significantly increased in mitochondriopathies, within the range of Niemann-Pick patients. Compared to the established biomarkers, CHIT1 and FGF21 showed a similar diagnostic performance, while better results were found for GDF15. However, there was a tendency for higher CHIT1 concentrations in patients with central nervous system involvement (MELAS syndrome), while FGF21 and GDF15 were not relevantly altered in these patients. Consequently, a combination of biomarkers including CHIT1 provided the best overall diagnostic performance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Serum CHIT1 concentration is significantly elevated in mitochondriopathies compared to healthy controls and other NMD, identifying CHIT1 as potential complementary biomarker in mitochondriopathies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00415-025-12916-5","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T14:59:27Z","timestamp":1738421967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Serum chitotriosidase-1 (CHIT1) as candidate biomarker for mitochondriopathies"],"prefix":"10.1007","volume":"272","author":[{"given":"Laura","family":"Foerster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Scholle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilka","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Stoltenburg-Didinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Stefan","family":"Delank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Strube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Koelsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Naegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander E.","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-4473","authenticated-orcid":false,"given":"Alexander","family":"Mensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"12916_CR1","first-page":"89","volume":"49","author":"FB Lagler","year":"2019","unstructured":"Lagler FB, Moder A, Rohrbach M et al (2019) Extent, impact, and predictors of diagnostic delay in Pompe disease: a combined survey approach to unveil the diagnostic odyssey. JIMD Rep 49:89\u201395","journal-title":"JIMD Rep"},{"key":"12916_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F et al (2022) Spinal muscular atrophy. Nat Rev Dis Primers 8:52","journal-title":"Nat Rev Dis Primers"},{"key":"12916_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091279","author":"B Labella","year":"2023","unstructured":"Labella B, Cotti Piccinelli S, Risi B et al (2023) A comprehensive update on late-onset pompe disease. Biomolecules. https:\/\/doi.org\/10.3390\/biom13091279","journal-title":"Biomolecules"},{"key":"12916_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","volume":"85","author":"Y An","year":"2005","unstructured":"An Y, Young SP, Kishnani PS et al (2005) Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85:247\u2013254","journal-title":"Mol Genet Metab"},{"key":"12916_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/jnnp-2017-317138","volume":"89","author":"P Steinacker","year":"2018","unstructured":"Steinacker P, Verde F, Fang L et al (2018) Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. J Neurol Neurosurg Psychiatry 89:239\u2013247","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12916_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1373\/clinchem.2012.190322","volume":"58","author":"JE Ho","year":"2012","unstructured":"Ho JE, Mahajan A, Chen M-H et al (2012) Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 58:1582\u20131591","journal-title":"Clin Chem"},{"key":"12916_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12885-019-5385-y","volume":"19","author":"Y Wang","year":"2019","unstructured":"Wang Y, Jiang T, Jiang M, Gu S (2019) Appraising growth differentiation factor 15 as a promising biomarker in digestive system tumors: a meta-analysis. BMC Cancer 19:177","journal-title":"BMC Cancer"},{"key":"12916_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","volume":"5","author":"MK Badman","year":"2007","unstructured":"Badman MK, Pissios P, Kennedy AR et al (2007) Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426\u2013437","journal-title":"Cell Metab"},{"key":"12916_CR9","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1096\/fj.10-165340","volume":"25","author":"D Cot\u00e1n","year":"2011","unstructured":"Cot\u00e1n D, Cordero MD, Garrido-Maraver J et al (2011) Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 25:2669\u20132687","journal-title":"FASEB J"},{"key":"12916_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/cells8010065","volume":"8","author":"D-S Lin","year":"2019","unstructured":"Lin D-S, Huang Y-W, Ho C-S et al (2019) Oxidative insults and mitochondrial DNA mutation promote enhanced autophagy and mitophagy compromising cell viability in pluripotent cell model of mitochondrial disease. Cells 8:65. https:\/\/doi.org\/10.3390\/cells8010065","journal-title":"Cells"},{"key":"12916_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165726","volume":"1866","author":"M Villanueva-Paz","year":"2020","unstructured":"Villanueva-Paz M, Povea-Cabello S, Villal\u00f3n-Garc\u00eda I et al (2020) Parkin-mediated mitophagy and autophagy flux disruption in cellular models of MERRF syndrome. Biochim Biophys Acta Mol Basis Dis 1866:165726","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"12916_CR12","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.bbadis.2015.08.027","volume":"1852","author":"J Garrido-Maraver","year":"2015","unstructured":"Garrido-Maraver J, Paz MV, Cordero MD et al (2015) Critical role of AMP-activated protein kinase in the balance between mitophagy and mitochondrial biogenesis in MELAS disease. Biochim Biophys Acta 1852:2535\u20132553","journal-title":"Biochim Biophys Acta"},{"key":"12916_CR13","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/cells10020420","volume":"10","author":"MU Kuk","year":"2021","unstructured":"Kuk MU, Lee YH, Kim JW et al (2021) Potential treatment of lysosomal storage disease through modulation of the mitochondrial-lysosomal axis. Cells 10:420. https:\/\/doi.org\/10.3390\/cells10020420","journal-title":"Cells"},{"key":"12916_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cca.2016.03.004","volume":"457","author":"S Kadali","year":"2016","unstructured":"Kadali S, Kolusu A, Sunkara S et al (2016) Clinical evaluation of chitotriosidase enzyme activity in Gaucher and Niemann Pick A\/B diseases: a retrospective study from India. Clin Chim Acta 457:8\u201311","journal-title":"Clin Chim Acta"},{"key":"12916_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288\u20131292","journal-title":"J Clin Invest"},{"key":"12916_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cca.2007.07.019","volume":"387","author":"F Isman","year":"2008","unstructured":"Isman F, Hobert JA, Thompson JN, Natowicz MR (2008) Plasma chitotriosidase in lysosomal storage diseases. Clin Chim Acta 387:165\u2013167","journal-title":"Clin Chim Acta"},{"key":"12916_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12967-017-1146-3","volume":"15","author":"I De Castro-Or\u00f3s","year":"2017","unstructured":"De Castro-Or\u00f3s I, Ir\u00fan P, Cebolla JJ et al (2017) Assessment of plasma chitotriosidase activity, CCL18\/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: a prospective observational study. J Transl Med 15:43","journal-title":"J Transl Med"},{"key":"12916_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jmg.2010.088096","volume":"48","author":"M Fuller","year":"2011","unstructured":"Fuller M, Tucker JN, Lang DL et al (2011) Screening patients referred to a metabolic clinic for lysosomal storage disorders. J Med Genet 48:422\u2013425","journal-title":"J Med Genet"},{"key":"12916_CR19","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/intimm\/dxh328","volume":"17","author":"M van Eijk","year":"2005","unstructured":"van Eijk M, van Roomen CPAA, Renkema GH et al (2005) Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol 17:1505\u20131512","journal-title":"Int Immunol"},{"key":"12916_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1432-1033.1997.00279.x","volume":"244","author":"GH Renkema","year":"1997","unstructured":"Renkema GH, Boot RG, Strijland A et al (1997) Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. Eur J Biochem 244:279\u2013285","journal-title":"Eur J Biochem"},{"key":"12916_CR21","doi-asserted-by":"publisher","first-page":"25680","DOI":"10.1074\/jbc.273.40.25680","volume":"273","author":"RG Boot","year":"1998","unstructured":"Boot RG, Renkema GH, Verhoek M et al (1998) The human chitotriosidase gene: nature of inherited enzyme deficiency. J Biol Chem 273:25680\u201325685","journal-title":"J Biol Chem"},{"key":"12916_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bcmd.2007.06.013","volume":"39","author":"P Lee","year":"2007","unstructured":"Lee P, Waalen J, Crain K et al (2007) Human chitotriosidase polymorphisms G354R and A442V associated with reduced enzyme activity. Blood Cells Mol Dis 39:353\u2013360","journal-title":"Blood Cells Mol Dis"},{"key":"12916_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jnnp-2018-318868","volume":"90","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Weydt P, Steinacker P et al (2019) Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. J Neurol Neurosurg Psychiatry 90:4\u201310","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12916_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1080\/21678421.2020.1861023","volume":"22","author":"P Steinacker","year":"2021","unstructured":"Steinacker P, Feneberg E, Halbgebauer S et al (2021) Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotroph Lateral Scler Frontotemporal Degener 22:276\u2013286","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"12916_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1196\/annals.1395.017","volume":"1100","author":"I Kurt","year":"2007","unstructured":"Kurt I, Abasli D, Cihan M et al (2007) Chitotriosidase levels in healthy elderly subjects. Ann N Y Acad Sci 1100:185\u2013188","journal-title":"Ann N Y Acad Sci"},{"key":"12916_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000506282","volume":"49","author":"IOC Woollacott","year":"2020","unstructured":"Woollacott IOC, Nicholas JM, Heller C et al (2020) Cerebrospinal fluid YKL-40 and chitotriosidase levels in frontotemporal dementia vary by clinical, genetic and pathological subtype. Dement Geriatr Cogn Disord 49:56\u201376","journal-title":"Dement Geriatr Cogn Disord"},{"key":"12916_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.5551\/jat.13920","volume":"20","author":"BS Yildiz","year":"2013","unstructured":"Yildiz BS, Barutcuoglu B, Alihanoglu YI et al (2013) Serum chitotriosidase activity in acute coronary syndrome. J Atheroscler Thromb 20:134\u2013141","journal-title":"J Atheroscler Thromb"},{"key":"12916_CR28","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000099099","volume":"108","author":"M Artieda","year":"2007","unstructured":"Artieda M, Cenarro A, Ga\u00f1\u00e1n A et al (2007) Serum chitotriosidase activity, a marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein. Cardiology 108:297\u2013306","journal-title":"Cardiology"},{"key":"12916_CR29","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3390\/antiox9100964","volume":"9","author":"J Cant\u00f3-Santos","year":"2020","unstructured":"Cant\u00f3-Santos J, Grau-Junyent JM, Garrabou G (2020) The impact of mitochondrial deficiencies in neuromuscular diseases. Antioxidants (Basel) 9:964. https:\/\/doi.org\/10.3390\/antiox9100964","journal-title":"Antioxidants (Basel)"},{"key":"12916_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.nmd.2014.03.009","volume":"24","author":"L Merlini","year":"2014","unstructured":"Merlini L, Nishino I, Consortium for Autophagy in Muscular Dystrophies (2014) 201st ENMC International Workshop: Autophagy in muscular dystrophies\u2013translational approach, 1\u20133 November 2013, Bussum, The Netherlands. Neuromuscul Disord 24:546\u2013561","journal-title":"Neuromuscul Disord"},{"key":"12916_CR31","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/ana.25143","volume":"83","author":"AG Thompson","year":"2018","unstructured":"Thompson AG, Gray E, Th\u00e9z\u00e9nas M-L et al (2018) Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol 83:258\u2013268","journal-title":"Ann Neurol"},{"key":"12916_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jns.2014.12.016","volume":"348","author":"V Pagliardini","year":"2015","unstructured":"Pagliardini V, Pagliardini S, Corrado L et al (2015) Chitotriosidase and lysosomal enzymes as potential biomarkers of disease progression in amyotrophic lateral sclerosis: a survey clinic-based study. J Neurol Sci 348:245\u2013250","journal-title":"J Neurol Sci"},{"key":"12916_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1875044301205010001","volume":"5","author":"M Kanneganti","year":"2012","unstructured":"Kanneganti M, Kamba A, Mizoguchi E (2012) Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol 5:1\u20139","journal-title":"J Epithel Biol Pharmacol"},{"key":"12916_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s13023-022-02495-3","volume":"17","author":"A Hanaford","year":"2022","unstructured":"Hanaford A, Johnson SC (2022) The immune system as a driver of mitochondrial disease pathogenesis: a review of evidence. Orphanet J Rare Dis 17:335","journal-title":"Orphanet J Rare Dis"},{"key":"12916_CR35","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1203\/01.pdr.0000233252.60457.cf","volume":"60","author":"J Reichenbach","year":"2006","unstructured":"Reichenbach J, Schubert R, Horv\u00e0th R et al (2006) Fatal neonatal-onset mitochondrial respiratory chain disease with T cell immunodeficiency. Pediatr Res 60:321\u2013326","journal-title":"Pediatr Res"},{"key":"12916_CR36","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/j.jaip.2019.03.046","volume":"7","author":"SK Kruk","year":"2019","unstructured":"Kruk SK, Pacheco SE, Koenig MK et al (2019) Vulnerability of pediatric patients with mitochondrial disease to vaccine-preventable diseases. J Allergy Clin Immunol Pract 7:2415-2418.e3","journal-title":"J Allergy Clin Immunol Pract"},{"key":"12916_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00325","volume":"21","author":"BJ Shayota","year":"2024","unstructured":"Shayota BJ (2024) Biomarkers of mitochondrial disorders. Neurotherapeutics 21:e00325","journal-title":"Neurotherapeutics"},{"key":"12916_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2016) A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87:539\u2013547","journal-title":"Neurology"},{"key":"12916_CR39","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1002\/jimd.12142","volume":"42","author":"PG Tsygankova","year":"2019","unstructured":"Tsygankova PG, Itkis YS, Krylova TD et al (2019) Plasma FGF-21 and GDF-15 are elevated in different inherited metabolic diseases and are not diagnostic for mitochondrial disorders. J Inherit Metab Dis 42:918\u2013933","journal-title":"J Inherit Metab Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12916-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12916-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12916-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T16:42:18Z","timestamp":1739637738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12916-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["12916"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12916-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AM has received speaking fees and advisory board honoraria from Hormosan and Sanofi, outside of the submitted work. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the institutional research committee of Martin-Luther-University of Halle-Wittenberg (vote no. 2021\u2013101). All subjects included in this study gave their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"180"}}